- Sales increased 6% with core sales up 1%.
- Net income rose 28% to $128 million.
- Adjusted EBITDA margin improved to 23.2%.
- $70 million returned to shareholders.
Financial Performance
Aptar's third quarter 2025 results show a 6% increase in reported sales and a 1% rise in core sales compared to the previous year. Net income increased by 28% to $128 million, with reported earnings per share up 30% to $1.92. Adjusted earnings per share, excluding non-ordinary-course litigation costs, rose 4% to $1.62.
Operational Highlights
The company experienced strong product volume growth in its Closures and Pharma divisions, particularly in injectables. Adjusted EBITDA increased by 7% to $223 million, with the adjusted EBITDA margin improving to 23.2% from 22.9% in the prior year.
Shareholder Returns
Aptar returned $70 million to shareholders through share repurchases and dividends during the third quarter. For the nine months year-to-date, the company returned $279 million to shareholders.
